Cardiogenesis

Cardiogenesis products focus on the treatment of refractory angina in patients with diffuse coronary artery disease(CAD). Patients with chronic angina (chest pain) are generally managed aggressively with medications to help alleviate their symptoms and frequently receive multiple coronary interventions and even bypass surgery over the course of the advancement of their disease. When chest pain continues in spite of treatments, the condition is considered, "refractory angina."

Coronary artery disease remains a leading cause of death for persons over the age of 65 in the United States. It is estimated that in the United States 100,000-200,000 symptomatic patients are diagnosed each year with refractory angina but are not candidates for further intervention or bypass surgery. A contemporary study indicates that as many of 3 out of 10 patients with CAD may have incomplete revascularization.

In addition to the TMR procedure, Cardiogenesis is developing proprietary catheter-based systems for the delivery of biologics, such as stem cells, as an adjunctive therapy for this patient population.